REAL-WORLD SAFETY, EFFECTIVENESS, AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION TREATED WITH GLECAPREVIR/PIBRENTASVIR:

Slides:



Advertisements
Similar presentations
Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV GT 4 Egyptian Ancestry Trial Phase 2 Ruane PJ, et al. J Hepatol. 2015;62:
Advertisements

Kwo PY. NEJM 2014;371: CORAL-I  Design OBV/PTV/r + DSV + RBV Open label Phase II years Chronic HCV infection, genotype 1 Liver transplantation.
NIAID ERADICATE Open-label W12 ≥ 18 years Chronic HCV infection Genotype 1 Treatment naïve HIV infection on stable ART ≥ 8 weeks and HIV RNA < 50 c/ml.
Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV Genotype 1 NIAID/NIH Trial Phase 2, Treatment Naïve Treatment Naïve (unfavorable.
Supplemental Figure Legends Supplemental Figure 1a: SF-36. SF-36 mental component score among subjects randomized to SAMe or placebo, at baseline, Week.
C-SALT Study: grazoprevir + elbasvir in genotype 1 with Child-Pugh B cirrhosis Jacobson IM. EASL 2015, Abs. O008  Design Child-Pugh B GZR 100 mg + EBR.
Hepatitis web study Hepatitis web study Elbasvir-Grazoprevir in Treatment-Naïve HCV Genotype 1, 4 or 6 C-EDGE Treatment Naïve (TN) Phase 3 Treatment Naïve.
Previous SVR With Interferon-Based Therapy for HCV Lowers Risk of Hepatotoxicity in HIV/HCV-Coinfected Individuals on Antiretroviral Therapy Slideset on:
Date of download: 7/10/2016 From: Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label,
ARV-trial.com RUBY-II Study: ombitasvir/paritaprevir/ritonavir + dasabuvir for HCV genotype 1a or 4 with severe renal impairment Design Open label W12.
eGFR (MDRD) > 50 mL/min
Where Are We on the Path to Elimination of Chronic Hepatitis C?
Interim Analysis of a 3-Year Follow-up Study of NS5A and NS3 Resistance-Associated Variants After Treatment With Grazoprevir-Containing Regimens in Patients.
EASL Recommendations on Treatment of Hepatitis C 2015 Treatment recommendations for HCV-monoinfected or HCV/HIV coinfected patients with chronic hepatitis.
Design Single arm Open label W12 ≥ 18 years, HCV genotype 1 to 6
C-ISLE study: EBR/GZR + SOF + RBV in genotype 3 and cirrhosis
Design Randomisation 2 : 1 Double-blind W12 ≥ 18 years, HCV genotype 3
No HBV or HIV co-infection
Phase 3 Treatment-Naïve and Treatment-Experienced
AL study: AL ODV + SMV in naïve patients, phase II
Phase 3b Treatment-Naive
Creatinine clearance ≥ 50 ml/min No HBV or HIV co-infection
Design Randomisation* 1 : 1 Open-label W12
Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study Liver Cancer.
Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis  Raoel Maan,
BACKGROUND MATERIALS & METHODS RESULTS CONCLUSIONS
Table 2. Mean intrasubject diversity for the 11 study participants, by genomic region. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects.
Chronic HCV Infection and CKD
HIV/HCV Co-Infection Case
DAA’s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?
Chronic Hepatitis C Virus Infection
Starting Strong: Initial Evaluation of the Patient With HCV
Phase 2 Treatment Naïve (unfavorable baseline treatment characteristics) Ledipasvir-Sofosbuvir +/- 3rd DAA in HCV Genotype 1 NIAID SYNERGY: Genotype.
Expanding the Universe of Viral Hepatitis Treaters
The Aging Liver in the Aging HIV and HCV Patients
Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.
Clinical Trials to Real World:
HCV Care in Unique Patient Populations
The HCV Revolution: Are You and Your Practice Ready?
Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/Grazoprevir/MK-8408 (Ruzasvir) With or Without Ribavirin in Non-cirrhotic or Cirrhotic.
Phase 2 Treatment Naïve Elbasvir + Grazoprevir +/- Ribavirin in Treatment-Naïve HCV GT 2, 4, 5, or 6 C-SCAPE Brown A, et al. EASL 2015; Abstract P0771.
Treatment with the second-generation HCV protease inhibitor BI results in high and consistent SVR rates: Results from SILEN-C1 in HCV genotype-1.
Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I
Virological tools to diagnose and monitor hepatitis C virus infection
Volume 149, Issue 4, Pages e1 (October 2015)
Novel Approaches in T1D Management
Phase 2 Treatment Naïve and Treatment Experienced
Clinical outcome after SVR: ANRS CO22 HEPATHER
Efficacy and Safety of Elbasvir/Grazoprevir in Treatment-Naïve patients with Chronic HCV GT 1, GT 4 and GT 6 Infection (C-CORAL): A Phase III Randomized.
A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match–control study  M.-C. Tsai,
Elbasvir/Grazoprevir plus Sofosbuvir ± Ribavirin in Treatment-naive and Treatment-experienced Patients with Hepatitis C Virus Genotype 3 Infection and.
A Real Life Study on Treatment of Egyptian Patients with HCV Genotype IV with Simeprevir and Sofosbuvir Prof.dr.Abdel fattah hanno Dr. Doaa al wazzan.
Trials and Tribulations in VTE: How Do Real-World Data Fit In?
Nghia H. Nguyen, Vincent Nguyen, Huy N. Trinh, Brian Lin, Mindie H
Phase 2 Treatment Naïve Elbasvir-Grazoprevir + Sofosbuvir in Treatment-Naïve HCV Genotype 1 or 3 C-SWIFT Poordad F, et al. EASL 2015; Abstract O006.
Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir  Zobair.
SOF/VEL in liver transplantation with genotype 1-4 infection
Volume 136, Issue 5, Pages (May 2009)
No HBV or HIV co-infection
Phase 3 Treatment-Naïve and Treatment-Experienced
Prevalence and Treatment of Hepatitis C Virus Genotypes 4, 5, and 6
Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682 / Grazoprevir / MK-8408 (Ruzasvir) in Cirrhotic or Non-cirrhotic Patients with Chronic.
Patient-reported outcomes: proportion of patients with clinically meaningful improvements in (A) SF-36 PCS and MCS at Week 52 and Week 104*†‡ and (B) HAQ-DI.
Phase 3 Treatment-Naïve and Treatment-Experienced
Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis.
Scott K. Fung, Anna S.F. Lok  Clinical Gastroenterology and Hepatology 
Kathleen E. Corey, Andrew S
Johannes Vermehren, James S. Park, Ira M. Jacobson, Stefan Zeuzem 
Sequencing cohorts Open-label Design W8 W12 ≥ 18 years
Pei-Yuan Su，Yu-Chun Hsu，Shun-Sheng Wu，Wei-Wen Su，Maw-Soan Soon
Presentation transcript:

REAL-WORLD SAFETY, EFFECTIVENESS, AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION TREATED WITH GLECAPREVIR/PIBRENTASVIR: DATA FROM THE GERMAN HEPATITIS C-REGISTRY

Disclosures

Disclosures

German Hepatitis C-Registry (DHC‐R)

Background and Objective

Study Population Receiving On-Label Glecaprevir/Pibrentasvir

Demographics and Clinical Characteristics at Baseline

Demographics and Clinical Characteristics at Baseline

SVR12 Rates in the Effectiveness Population

SVR12 Rates in the Effectiveness Population

SVR12 Rates in HCV Treatment-Naïve Non-Cirrhotic Patients

SF-36 Component Summary Scores at Baseline

SF-36 Physical Component Summary Score

SF-36 Mental Component Summary Score

Safety

Summary

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.